Le Lézard
Classified in: Health, Science and technology
Subjects: PLW, MAT

MMJ International Holdings Files US Patent Prior To FDA Study For Cannabinoid Treatment Medicine



RESTON, Va., Jan. 3, 2018 /PRNewswire-PRWeb/ -- MMJ International Holdings, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and the operation of medical cannabis healthcare businesses, today announced that it has filed another patent invention with the United States Patent and Trademark Office that relates to pharmaceutical compounds and methods for treating and/or preventing symptoms associated with cannabinoid responsive diseases and disorders, such as Multiple Sclerosis (MS), and Huntington's disease (HD).

MMJ BioScience's disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amounts of a pharmaceutical compound containing cannabinoids to Multiple Sclerosis (MS) and Huntington's (HD) disease patients in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.The MMJ BioScience has filed these patents to protect the delivery of its MMJ BioScience® product formulation for its upcoming multiple sclerosis FDA study which is progressing through the Federal Drug Administrations (FDA) regulatory process.

Dr. Bianca Weinstock-Guttman, MMJ BioScience's principal investigator, is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium. Dr. Weinstock-Guttman will oversee the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients.

In late 2017 MMJ BioScience had submitted an application with the United States Food and Drug Administration (FDA) for approval of a new pharmaceutical drug. Unlike other cannabis-type medicines, MMJ BioScience's medicine is plant derived. When approval is received from the FDA the new medicine would be on sale across America as an approved drug.

MMJ BioScience's expected approval by the FDA for its new medicine would have a major impact on the state to state emerging cannabis industry which is not federally legal. Most recently the FDA had issued several cease and desist letters to firms that are marketing unapproved cannabinoid products. Whereas non-pharmaceutical companies cannot export their products across state lines, MMJ BioScience would be able to sell its medicine in pharmacies once prescribed by physicians.

MMJ BioScience's discovery of a novel cannabinoid pharmacology through our network of world leading scientists, our intellectual property portfolio, proprietary formulations, processing, and regulatory expertise uniquely position us to develop and manufacture plant-derived cannabinoid formulations at sufficient quality and uniformity according to the FDA regulatory requirements for pharmaceutical development.

 

SOURCE MMJ International Holdings


These press releases may also interest you

at 16:33
Cellular Biomedicine Group Inc. (CBMG or the Company), a leading...

at 16:17
Pfizer Canada has advised Health Canada that there is currently a shortage of EpiPen auto-injectors in the 0.3 mg format (DIN 00509558). The shortage is reported to be due to a manufacturing disruption and is currently anticipated to be resolved by...

at 16:13
Robb Report has announced its third annual Health + Wellness experience, taking place March 15?18, 2018, at 1 Hotel South Beach in Miami Beach, Fla. Just in time for the upkeep of wellness-themed New Year's resolutions, the annual event returns with...

at 16:10
Americans depend on the U.S. Food and Drug Administration to help ensure that the products they buy are safe. Last month, I committed the agency to further improve our recall processes because I believe that consumers should have actionable...

at 16:05
QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA supplement extending the indications for use of QIAGEN's therascreen® EGFR RGQ PCR Kit as a companion diagnostic to guide the use of Boehringer...

at 16:05
Natural Grocers by Vitamin Cottage, Inc. today announced that the Company will release its first quarter fiscal year 2018 financial results after the market close on Thursday, February 1, 2018. Following the release via the wire services, the...




News published on 3 january 2018 at 13:00 and distributed by: